Cargando…
The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC
BACKGROUND: There remains up to a 50% recurrence rate in advanced p16- head and neck squamous cell carcinoma with current standard of care treatment. In an attempt to improve survival, multiple trials administering induction or neoadjuvant chemotherapy have been conducted but none demonstrated impro...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077151/ https://www.ncbi.nlm.nih.gov/pubmed/32195008 http://dx.doi.org/10.1186/s41199-020-00052-8 |